Quarterly ResultMay 7, 2026, 04:25 PM
Kodiak Sciences Q1 Net Loss $58.2M; Going Concern Doubt Raised
AI Summary
Kodiak Sciences reported a net loss of $58.2 million for Q1 2026, a slight increase from $57.5 million in Q1 2025. The company's cash and cash equivalents decreased to $169.5 million from $209.9 million at the end of 2025, and net cash used in operating activities increased significantly to $40.0 million. Management has raised substantial doubt about the company's ability to continue as a going concern, citing insufficient cash to meet anticipated operating and capital expenditure requirements for the next 12 months.
Key Highlights
- Substantial doubt raised about Kodiak Sciences' ability to continue as a going concern.
- Net loss for Q1 2026 was $58.2 million, compared to $57.5 million in Q1 2025.
- Cash and cash equivalents decreased to $169.5 million as of March 31, 2026, from $209.9 million.
- Net cash used in operating activities increased to $40.0 million from $29.1 million year-over-year.
- Research and development expenses rose to $48.5 million from $43.6 million in Q1 2025.
- General and administrative expenses decreased to $11.2 million from $15.4 million in Q1 2025.
- Net loss per share was $(0.94) for Q1 2026, an improvement from $(1.09) in Q1 2025.